James E. Brown, D.V.M.
James E. Brown, D.V.M., co-founded DURECT in 1998 and has served as President, Chief Executive Officer and a Director since June of that year. DURECT is a publicly-traded specialty pharmaceutical company with two late-stage products in development. The first of these is REMOXY®, an abuse-deterrent formulation of oxycodone for the treatment of chronic pain, in development by Pfizer. The second is POSIDUR™ a controlled release formulation of bupivacaine for the treatment of post-operative pain. DURECT has a number of earlier stage programs as well as two commercial product lines, the ALZET® osmotic mini-pump and LACTEL® Absorbable Polymers.
Prior to founding DURECT, Dr. Brown worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development. Before working at ALZA, Dr. Brown held various positions at Syntex Corporation including Director of Business Development, Director of Joint Ventures for Discovery Research, and Program Director for Syntex Research and Development. He began his career in the biopharmaceutical industry working at SYVA, a medical diagnostics company. He has served on a number of boards including St. Francis High School in Mountain View, California.
Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis.